Tema Oncology ETF (NASDAQ:CANC) Short Interest Up 232.7% in January

Posted by Trent Williams on Feb 13th, 2025

Tema Oncology ETF (NASDAQ:CANC – Get Free Report) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 16,300 shares, a growth of 232.7% from the January 15th total of 4,900 shares. Based on an average daily volume of 18,000 shares, the days-to-cover ratio is currently 0.9 days.

Tema Oncology ETF Stock Performance

Shares of CANC traded up $0.29 during mid-day trading on Thursday, hitting $25.25. 7,461 shares of the company’s stock were exchanged, compared to its average volume of 28,870. The stock’s 50-day moving average is $25.19 and its 200-day moving average is $27.23. The company has a market cap of $64.38 million, a price-to-earnings ratio of 26.86 and a beta of 1.11. Tema Oncology ETF has a fifty-two week low of $23.97 and a fifty-two week high of $30.11.

Tema Oncology ETF Announces Dividend

The business also recently declared a dividend, which was paid on Thursday, December 12th. Shareholders of record on Wednesday, December 11th were paid a $0.7283 dividend. The ex-dividend date was Wednesday, December 11th.

Hedge Funds Weigh In On Tema Oncology ETF

A hedge fund recently raised its stake in Tema Oncology ETF stock. Thrivent Financial for Lutherans boosted its position in Tema Oncology ETF (NASDAQ:CANC – Free Report) by 25.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 399,509 shares of the company’s stock after buying an additional 80,133 shares during the period. Thrivent Financial for Lutherans owned approximately 22.96% of Tema Oncology ETF worth $11,351,000 as of its most recent SEC filing.

Tema Oncology ETF Company Profile

(Get Free Report)

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.